MedPath

EHRA-PATHS: Clinical and Health Economic Evaluation of New Care Pathways

Not Applicable
Recruiting
Conditions
Atrial Fibrillation
Interventions
Device: EHRA-PATHS software tool
Registration Number
NCT05773768
Lead Sponsor
University Medical Center Groningen
Brief Summary

In elderly atrial fibrillation (AF) patients, AF is usually a manifestation of risk factors and comorbidities not only limited to cardiovascular diseases. Especially in elderly often more than two comorbidities are present. The presence of comorbidities also affects outcomes in AF patients. Current healthcare systems are single-disease focused, which increases the risk of underdiagnosing, replicating diagnostic tests and adverse drug-drug interactions, placing a high burden on healthcare costs. Healthcare systems and hospitals are in need of new care pathways to address the complexity of multimorbid AF patients and to reduce costs. The EHRA-PATHS consortium set out to address this need for change in management for multimorbid, elderly AF patients in Europe through the development of new care pathways. The aim of this study is to evaluate the current management of risk factors and comorbidities, and subsequently implement the newly developed care pathways and evaluate if these pathways lead to better management of risk factors and comorbidities in multimorbid, elderly AF patients, compared to current standard care.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1300
Inclusion Criteria
  • Newly diagnosed atrial fibrillation (paroxysmal, persistent or permanent)
  • ≥65 years of age
  • Willing and able to participate and to attend the scheduled follow-up visits.
Exclusion Criteria
  • Atrial fibrillation episode was due to a trigger (i.e. postoperative, infection, hyperthyroidism etc.)
  • Life expectancy of less than 1 year
  • Participation in another clinical study (registry studies not included)
  • Severe cognitive impairment / dementia (defined based on MMSE and CDR scoring systems)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
New care programEHRA-PATHS software toolThe health care provider will use the EHRA-PATHS' newly developed care pathways to assess whether there is an indication for presence of risk factors and comorbidities. If this is the case, the care pathways will show possible next steps for confirming the presence of these risk factors and comorbidities. If confirmed, treatment according to the current guidelines should be initiated. Since this leads to an individualized management plan, procedures can differ between patients and will also depend on local processes.
Primary Outcome Measures
NameTimeMethod
Identification and management of risk factors and comorbidities6 months

The number of risk factors and comorbidities that are identified and for which treatment is initiated during base mapping and at the end of the randomized controlled trial.

Secondary Outcome Measures
NameTimeMethod
Referrals to other disciplines6 months

The referrals to other disciplines will consist of the number of referrals and the percentage of patients referred.

HRQoL/utility6 months

Measured with the EQ-5D-5L questionnaire (iMCQ)

AF symptom burden6 months

Measured with the Atrial Fibrillation Severity Scale (AFSS) questionnaire

Quality of life (QoL)6 months

Measured with the EuroQol five-dimensional five-level (EQ-5D-5L) questionnaire

Patient and health care provider satisfaction6 months

Measured with a patient and health care provider (HCP) satisfaction questionnaire

Healthcare resource use/costs6 months

Measured with the iMedical Consumption Questionnaire (iMCQ)

Trial Locations

Locations (1)

University Medical Center Groningen

🇳🇱

Groningen, Netherlands

© Copyright 2025. All Rights Reserved by MedPath